TELIX PHARMACEUTICALS LIMITED.
Australian public company
- Reports this week
- 0
- Active events
- 0
- Connections
- 48
What's happening
Earlier this month
One to three months ago
-
Merger aims to create a vertically integrated radiopharmaceutical leader.Some support3 reports
-
Telix Pharmaceuticals Limited announced that it is utilizing the Nasdaq exchange for its ADR listing.Some support2 reports
-
TELIX Pharmaceuticals is conducting Phase 3 trials and seeking alignment on the New Drug Application pathway with the FDA.Some support11 reports
-
Telix Pharmaceuticals Limited, headquartered in Melbourne, has international operations including in Europe and is listed on the Australian Securities Exchange.Well supported12 reports
Gone quiet
No new reports in 90+ days-
Telix Pharmaceuticals Limited and Regeneron announced a collaboration on May 1, 2026, to jointly develop next-generation radiopharmaceuticals.Some support2 reports
-
A company is developing Gozzellix, a next-generation PSMA-PET imaging agent, for prostate cancer treatment, benefiting from Trump-era tariffs and AI stocks.Some support2 reports1 development inside
-
Strategic research partnership established in the US between TELIX PHARMACEUTICALS LIMITED and United Imaging Healthcare.Some support1 report
-
Telix Pharmaceuticals Limited is headquartered in Melbourne, Australia, and an executive is attending a conference in Chicago.Well supported4 reports1 development inside
-
Telix Pharmaceuticals Limited is involved in activities related to Europe.Speculative1 report
-
Telix Pharmaceuticals acquired RLS and received FDA approval for a label expansion of its drug Illuccix.Speculative2 reports
No events began in the chosen period. Widen it, or reset.
What's reaching TELIX PHARMACEUTICALS LIMITED
Events traced to TELIX PHARMACEUTICALS LIMITED, step by step, newest firstExplainers that pass through TELIX PHARMACEUTICALS LIMITED
TELIX PHARMACEUTICALS LIMITED is a step on the way to someone elseAround TELIX PHARMACEUTICALS LIMITED this week
News at the entities that move TELIX PHARMACEUTICALS LIMITED most-
Australian Securities Exchange StructuralFirmus is seeking an IPO on the Australian Securities Exchange (ASX) while maintaining operational data centers in Singapore and Australia.Moves TELIX PHARMACEUTICALS LIMITED
-
MarketBeat Mentioned togetherKeefe, Bruyette & Woods lifted its price objective for TMP, with MarketBeat providing consensus rating data.Moves TELIX PHARMACEUTICALS LIMITED
-
FDA StructuralFDA conducted a nationwide product recall involving toothpaste flavored with strawberry and watermelon, featuring Barbie characters.Moves TELIX PHARMACEUTICALS LIMITED
-
Citigroup TransactionalBiographical details about Ajaypal Singh Banga, including his birthplace, education, and joining Citigroup.Moves TELIX PHARMACEUTICALS LIMITED
-
Food and Drug Administration StructuralFDA conducted a search operation in Pune on January 1, 2026.Moves TELIX PHARMACEUTICALS LIMITED
-
Nasdaq StructuralPintec Technology trades on the Nasdaq exchange.Moves TELIX PHARMACEUTICALS LIMITED
Connections
The 17 strongest of 48, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Australian Securities Exchange Structural
Telix is a company formally listed on the Australian Securities Exchange.
-
FDA Structural
Telix Pharmaceuticals relies on the FDA for regulatory approvals, label expansions, and pathway alignment of its pharmaceutical products.
-
Nasdaq Structural
Telix Pharmaceuticals Limited is formally listed on the Nasdaq stock exchange.
-
PR Newswire Structural
Telix utilizes PR Newswire's service for the distribution of company press releases.
-
Citigroup Transactional
Citigroup reiterated a buy rating on the shares of Telix Pharmaceuticals Limited.
-
Lazard Asset Management LLC Transactional
Lazard Asset Management LLC increased its institutional stake in Telix Pharmaceuticals Limited.
-
Novartis Operational
Telix Pharmaceuticals competes directly with Novartis by developing drugs targeting the same indications as Novartis's Lutathera and Pluvicto.
-
Food and Drug Administration Structural
The FDA's regulatory alignment is shown to advance TELIX PHARMACEUTICALS LIMITED's clinical trials.
Show all 17 connections
-
MarketBeat Mentioned together
MarketBeat, a financial data aggregator, provides coverage and stock ratings for Telix Pharmaceuticals.
-
Belgium Shared context
Telix operates internationally within the geographical context of Belgium.
-
Switzerland Shared context
Telix Pharmaceuticals Limited has international operations within Switzerland.
-
Europe Shared context
Telix Pharmaceuticals Limited conducts international operations within Europe.
-
Sydney Shared context
The company's stock performance is benchmarked against the conditions and market context of Sydney.
-
Melbourne Shared context
Telix Pharmaceuticals Limited is headquartered and conducts operations within Melbourne.
-
New York City Shared context
Telix Pharmaceuticals utilizes New York City as the location for its corporate events, including Investor Day and R&D Day.
-
Royal Bank of Canada Mentioned together
A's shares received a moderate buy rating, indicating market coverage or analysis by B.
-
Munich Shared context
The company is involved in a strategic merger aimed at creating a vertically integrated radiopharmaceutical leader, with the partner based in Munich.
History
Events by the month they beganOctober 2026
1 eventSeptember 2026
4 events- Telix agreed to acquire ITM Isotope Technologies Munich and is developing drugs that compete with Novartis.
- Merger aims to create a vertically integrated radiopharmaceutical leader.
- Telix Pharmaceuticals Limited announced that it is utilizing the Nasdaq exchange for its ADR listing.
- TELIX Pharmaceuticals is conducting Phase 3 trials and seeking alignment on the New Drug Application pathway with the FDA.
July 2026
1 eventShow 1 earlier month
June 2026
6 events- Telix Pharmaceuticals Limited, headquartered in Melbourne, has international operations including in Europe and is listed on the Australian Securities Exchange.
- A company is developing Gozzellix, a next-generation PSMA-PET imaging agent, for prostate cancer treatment, benefiting from Trump-era tariffs and AI stocks.
- Strategic research partnership established in the US between TELIX PHARMACEUTICALS LIMITED and United Imaging Healthcare.
- Telix Pharmaceuticals Limited is headquartered in Melbourne, Australia, and an executive is attending a conference in Chicago.
- Telix Pharmaceuticals Limited is involved in activities related to Europe.
- Telix Pharmaceuticals acquired RLS and received FDA approval for a label expansion of its drug Illuccix.